Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR

dc.authoridşen, nesrin/0000-0003-0966-0075
dc.authoridEcesoy, Hilal/0000-0001-9274-168X
dc.authoridSunar, Ismihan/0000-0002-4435-5677
dc.authoridkacar, cahit/0000-0002-1632-1621
dc.authoridKaya, Taciser/0000-0002-8848-8420
dc.authoridAyhan, Fikriye Figen/0000-0001-6906-991X
dc.authoridAtaman, Sebnem/0000-0003-3570-3825
dc.authorwosidşen, nesrin/ABI-6368-2020
dc.authorwosidEcesoy, Hilal/AAK-4471-2021
dc.authorwosidSoy, derya nazlı/JYP-8948-2024
dc.authorwosidAltay, Zuhal/AAC-4361-2021
dc.authorwosidcapkin, erhan/D-6630-2015
dc.authorwosidSunar, Ismihan/AAB-7763-2019
dc.authorwosidKaya, Zuhre/AAA-7871-2022
dc.contributor.authorAtaman, Sebnem
dc.contributor.authorSurmeli, Zuhre Sari
dc.contributor.authorSunar, Ismihan
dc.contributor.authorOzdemirel, Erhan
dc.contributor.authorAkinci, Aysen
dc.contributor.authorBodur, Hatice
dc.contributor.authorAkgul, Ozgur
dc.date.accessioned2024-08-04T20:09:48Z
dc.date.available2024-08-04T20:09:48Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey. Materials and methods: Members of Turkish League Against Rheumatism and one rheumatoid arthritis patient voted for the 2013 recommendations of the European League Against Rheumatism for treatment of rheumatoid arthritis in two sessions. An item was changed and voted again only if at least 70% of participants wanted a change. Strength of recommendations was calculated for the items. Strength of recommendations for the changed items in the first and second voting rounds was compared by Wilcoxon signed-rank test. In case of significant difference, the item with higher strength of recommendation was accepted. In case of no difference, the changed item was selected. Results: Three overarching principles and fourteen recommendations were assessed among which the three overarching principles were changed emphasizing the importance of physiatrists as well as rheumatologists for taking care of the patients. Third item was changed by adding composite indices for assessing disease activity. In the ninth recommendation, rituximab was suggested as a first line drug independent of situations like latent tuberculosis or lymphoma, etc. In the 11th recommendation, unlike European League Against Rheumatism, our committee did not suggest any thought about tofacitinib, as then it had not been approved in Turkey. Remaining principles were accepted as the same. Conclusion: Expert opinion of Turkish League Against Rheumatism for treatment of rheumatoid arthritis patients was formed for practices in Turkish clinics.en_US
dc.identifier.doi10.5606/ArchRheumatol.2015.5654
dc.identifier.endpage284en_US
dc.identifier.issn2148-5046
dc.identifier.issn1309-0283
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84949207430en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage271en_US
dc.identifier.trdizinid189349en_US
dc.identifier.urihttps://doi.org/10.5606/ArchRheumatol.2015.5654
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/189349
dc.identifier.urihttps://hdl.handle.net/11616/92449
dc.identifier.volume30en_US
dc.identifier.wosWOS:000366027100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherTurkish League Against Rheumatismen_US
dc.relation.ispartofArchives of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiologic disease modifying anti-rheumatic drugsen_US
dc.subjectrheumatoid arthritisen_US
dc.subjectsynthetic disease modifying anti-rheumatic drugsen_US
dc.subjecttreatment recommendationsen_US
dc.titleTurkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLARen_US
dc.typeArticleen_US

Dosyalar